BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 05:15PM GMT
Release Date Price: €24.2 (+0.33%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Welcome to Day 1 of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here. And today, we have we have Vimal Mehta, the CEO; Rob Risinger, Chief Medical Officer; and Matt Wiley, Chief Commercial Officer of BioXcel. Thanks, guys, for joining us. Vimal, would you like to start off with any opening remarks, and then we'll jump into Q&A?

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Thanks, Greg. Thank you, everyone, for joining us this morning. It's an extremely exciting time for BioXcel Therapeutics. We had our earnings call yesterday, so we laid it out why 2023 is extremely exciting. But I will highlight a couple of things. One, that our IGALMI launch, which is our commercial product for treatment of acute agitation resulting from schizophrenia bipolar 1 and 2 in adults, is progressing very well. And Matt is going to provide you more color around it. In addition to that, that opportunity allows us to capture 16

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot